Related Experiment Video
Updated: Jun 14, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer
N M A White1, T-F F Chow, S Mejia-Guerrero
1Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada.
Background:
Kallikrein-related peptidases (KLKs) are a family of serine proteases that have been shown to be dysregulated in several malignancies including ovarian cancer. The control of kallikrein genes and their physiological function in cancer is not well understood. We hypothesized that microRNAs (miRNAs) represent a novel mechanism for post-transcriptional control of KLK expression in cancer.
Methods:
We first analysed miRNA expression in ovarian cancer in silico. A total of 98 miRNAs were reported to have altered expression in ovarian cancer. Three of these miRNAs were predicted to target KLK10. We experimentally verified the predicted miR-KLK10 interaction using two independent techniques, a luciferase assay with a construct containing the KLK10 3' untranslated region (UTR), pMIR-KLK10, and measuring KLK10 protein levels after transfection with miRNA.
Results:
When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. We then examined the effect of these three miRNAs on KLK10 protein expression and cell growth. Transfection of all miRNAs, let-7f, miR-224, and miR-516a led to a decrease in protein expression and cellular growth. This effect was shown to be dose dependent. The KLK10 protein levels were partially restored by co-transfecting let-7f and its inhibitor. In addition, there was a slight decrease in KLK10 mRNA expression after transfection with let-7f.
Conclusion:
Our results confirm that KLKs can be targeted by more than one miRNA. Increased expression of certain miRNAs in ovarian cancer can lead to decreased KLK protein expression and subsequently have a negative effect on cell proliferation. This dose-dependent effect suggests that a 'tweaking' or 'fine-tuning' mechanism exists in which the expression of one KLK can be controlled by multiple miRNAs. These data together suggest that miRNA may be used as potential therapeutic options and further studies are required.
Insights
MicroRNAs (miRNAs) fine-tune kallikrein-related peptidase (KLK) expression in ovarian cancer. Increased miRNA levels reduce KLK protein, inhibiting cell growth, suggesting potential miRNA-based therapies.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Kallikrein-related peptidases (KLKs) are serine proteases implicated in various cancers, including ovarian cancer.
- Dysregulation of KLK gene expression in cancer is not fully understood.
- MicroRNAs (miRNAs) are investigated as potential post-transcriptional regulators of KLK expression in malignancy.
Purpose of the Study:
- To investigate the role of miRNAs in regulating KLK expression in ovarian cancer.
- To identify specific miRNAs targeting KLK10.
- To determine the functional impact of miRNA-KLK10 interaction on ovarian cancer cell proliferation.
Main Methods:
- In silico analysis of miRNA expression in ovarian cancer.
- Luciferase reporter assays to verify miRNA-KLK10 interaction.
- Measurement of KLK10 protein and mRNA levels following miRNA transfection.
- Assessment of cell growth after miRNA transfection.
Main Results:
- Three miRNAs (let-7f, miR-224, miR-516a) were predicted and experimentally validated to target KLK10.
- Transfection with these miRNAs decreased KLK10 protein expression and ovarian cancer cell growth in a dose-dependent manner.
- KLK10 protein levels were partially restored by co-transfection with let-7f inhibitor, and a slight decrease in KLK10 mRNA was observed.
Conclusions:
- KLKs can be targeted by multiple miRNAs, indicating a complex regulatory network.
- Increased expression of specific miRNAs in ovarian cancer can suppress KLK protein levels and inhibit cell proliferation.
- These findings highlight the potential of miRNAs as therapeutic targets for ovarian cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
